Group B streptococcus (GBS) remains worldwide a leading cause of severe neonatal
disease. Since the end of the 1990s, various strategies for prevention of the early onset …

Abstract Group B Streptococcus (GBS) emerged as the leading cause of newborn infection
in the United States in the 1970s. In the 1980s clinical trials demonstrated that giving …

Background Early‐onset group B streptococcal (EOGBS) disease (including sepsis,
meningitis, and pneumonia) causes significant morbidity and mortality in newborn infants …

Group B streptococcus is a leading cause of serious neonatal infection. Most neonatal GBS
infections can be prevented through the use of intrapartum antimicrobial prophylaxis in …

This Policy Statement was retired January 2015. The Centers for Disease Control and
Prevention (CDC) guidelines for the prevention of perinatal group B streptococcal (GBS) …

Abstract Background: Group B streptococcus (GBS) is an important cause of neonatal
sepsis. Guidelines advise to collect cultures at 35–37 weeks' gestation and to administer …

OBJECTIVE: To examine published evidence regarding duration of intrapartum antibiotic
prophylaxis administered to pregnant women colonized with group B Streptococcus (GBS) …

Background: Most early-onset group B streptococcal (GBS) disease in recent years has
occurred in newborns of prenatally GBS-negative mothers who missed intrapartum antibiotic …

Group B streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis.
Despite optimal treatment of GBS-infected neonates it is associated with significant morbidity …

Background. Intrapartum antibiotic prophylaxis is currently given to mothers who test positive
for group B streptococcus (GBS) by antenatal culture-based screening, with a risk-based …